The United Kingdom is one of Gavi’s six founding donors and a long-standing champion of immunisation, global health security and innovative development financing. Beginning with its founding role in Gavi’s establishment in 2000, the UK has supported the Alliance through major funding channels, including direct contributions; the International Finance Facility for Immunisation (IFFIm); the Pneumococcal Advance Market Commitment (AMC); the African Vaccine Manufacturing Accelerator (AVMA); the Gavi Matching Fund; and the Gavi COVAX AMC. As Gavi’s largest donor and the leading donor to IFFIm, the UK continues to have a central role in accelerating access to life-saving vaccines and advancing global health security. 

This partnership aligns closely with the UK’s international development priorities by strengthening national systems, supporting locally led and sustainable solutions, and leveraging finance, partnerships and expertise to maximise long-term impact.

On 25 June 2025, the UK Government pledged £1.25 billion (~US$ 1.7 billion) to support Gavi’s 2026–2030 strategic period. This includes £685 million in direct grant funding, of which £25 million is for the Gavi Matching Fund; a £300 million commitment to IFFIm; and approximately £370 million (US$ 496 million) in proceeds from existing IFFIm commitments and recommitment of funds. This comes alongside an existing commitment of £49 million to AVMA.

The UK also played a leading role in the global response to COVID-19, committing £548 million in support to the Gavi COVAX AMC via IFFIm financing and recommitting funds from the Pneumococcal AMC following its successful closure. The Foreign, Commonwealth & Development Office continues to conduct annual reviews and Central Assurance Assessments of its investments in Gavi and IFFIm, recognising their strong impact and value for money, with consistent A and A+ ratings respectively. Through more than two decades of partnership with Gavi, the UK has helped expand equitable access to vaccines, protect communities from infectious disease threats, and improve the health and prosperity of millions of children around the world.

Gavi is committed to the proper use of its resources and to the highest standards of integrity. Concerns relating to fraud, corruption, bribery, theft, safeguarding violations, or other misuse of Gavi resources can be reported through Gavi’s Ethics hotline.

Where a concern specifically relates to funding provided by the UK Foreign, Commonwealth & Development Office (FCDO), individuals may also report it directly to the FCDO Internal Audit and Investigations Directorate at reportingconcerns@fcdo.gov.uk or +44 (0)1355 843747.

Proceeds to Gavi 6.0 as of 30 June 2026†
Contributions to Gavi Board approved financing instruments

*Local currency

†Proceeds are the funds that Gavi receives from donor commitments, either through direct donor payments, funding raised in advance against future donor pledges through IFFIm, or AMC funds released by the World Bank.

Contributions and pledges per strategic period (US$ millions)

Hover over the bar chart above to view the data

Direct Contributions (including Matching Fund)

Non-US$ contributions are converted to US$ as follows:

  • Before Gavi 6.0 (2000–2025): exchange rate on date of receipt; where hedged (2014–2025), the hedge rate applies instead.
  • Gavi 6.0 (2026 onward, received & future contributions and Matching Fund Pledges): Bloomberg replenishment rate, 16:00 London time, 25 June 2025.

IFFIm Contributions

Non-US$ contributions are converted to US$ as follows:

  • Received Contributions: rate confirmed by the World Bank's International Bank for Reconstruction and Development (IBRD).
  • Future, signed contribution agreements: exchange rate at time of signing.
  • Future, unsigned contribution agreements: Bloomberg replenishment rate, 16:00 London time, 25 June 2025.

 

All donors